JRC News

  1. 4 Feb 2016

    Cancer is one of the main causes of death in the EU, responsible for almost 1.3 million deaths in 2013, according to Eurostat.

  2. 21 Dec 2015

    Targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system, according to a recent study co-authored by the JRC.

  3. 2 Oct 2015

    A JRC invention initially stemming from its research in the nuclear sector will soon be used by hospitals for minimally-invasive robotic surgery.

  4. 23 Sep 2015

    A novel, accelerator-driven method could produce nuclides for targeted alpha therapy of cancer in practically unlimited amounts, overcoming current obstacles for its wider use due to a limited production of alpha-emitters.

  5. 25 Mar 2015

    A new treatment for bladder carcinoma is being developed by the JRC and Munich’s Technical University hospital Klinikum rechts der Isar. Recently, the first in-human tests have been conducted showing positive results.

  6. 13 Jan 2015

    The Institute for Transuranium Elements (JRC-ITU) of the European Commission, the Medical University Warsaw and Eckert & Ziegler Eurotope invite you to the 9th Symposium on Targeted Alpha Therapy.

  7. 29 Oct 2014

    A study evaluating the immunogenicity of tumour cells after they have been irradiated with the alpha particle emitter bismuth-213 (213Bi) showed resistance to further tumour challenge.

  8. 12 Jun 2012

    A picture is worth a thousand words. This is the reason why the image shown has been awarded the title of "image of the year" by the Society of Nuclear Medicine (SNM). It comes from a study led by the Joint Research Centre´s (JRC) Institute for Transuranium Elements (ITU) and conducted in collaboration with University Hospital Heidelberg

  9. 1 Dec 2011

    Invasive fungal infections (IFI) are a major threat to individuals with cancer, transplants, HIV, and other conditions that weaken their immune system. New research has shown that radioimmunotherapy (RIT) could be a promising avenue for development of new types of treatment of fungal diseases. The research is published in a paper co-authored by JRC scientists in the framework of collaboration with the Albert Einstein College of Medicine (AECM) in New York.

  10. 20 Jul 2011

    Experts from medicine, biology, chemistry and physics gathered in Berlin on 18 and 19 July for the 7th Symposium on Targeted Alpha Therapy, organised by the JRC's Institute for Transuranium Elements (ITU) and engineering company Eckert & Ziegler Eurotope GmbH.